Literature DB >> 1714718

Prostaglandins E2 and F2a mediate the increase in c-myc expression induced by EGF in primary rat hepatocyte cultures.

G G Skouteris1, M R Kaser.   

Abstract

Epidermal Growth Factor (EGF) and prostaglandins (PGs) E2 and F2a, have been shown to stimulate primary hepatocyte proliferation. Verapamil (5-20 microM), a calcium channel inhibitor, inhibited hepatocyte DNA synthesis and c-myc expression, induced by EGF (50 ng/dish) and prostaglandins (1-12 micrograms/dish). Indomethacin (20-100 microM) decreased significantly the EGF-induced hepatocyte DNA synthesis and c-myc expression. Addition of PGs (1-9 micrograms) in hepatocyte cultures treated with EGF+indomethacin (100 microM) restored the capacity of EGF to increase c-myc expression and DNA synthesis. We propose that arachidonic acid derivatives and calcium channel blockers modulate c-myc expression in primary hepatocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714718     DOI: 10.1016/0006-291x(91)91026-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

Review 1.  Hepatocyte growth factor/scatter factor-induced intracellular signalling.

Authors:  K A Stuart; S M Riordan; S Lidder; L Crostella; R Williams; G G Skouteris
Journal:  Int J Exp Pathol       Date:  2000-02       Impact factor: 1.925

2.  C-myc is required for the G0/G1-S transition of primary hepatocytes stimulated with a deleted form of hepatocyte growth factor.

Authors:  G G Skouteris; C H Schröder
Journal:  Biochem J       Date:  1996-06-15       Impact factor: 3.857

3.  Transforming growth factor-alpha-induced DNA synthesis and c-myc expression in primary rat hepatocyte cultures is modulated by indomethacin.

Authors:  G G Skouteris; M McMenamin
Journal:  Biochem J       Date:  1992-02-01       Impact factor: 3.857

4.  Inhibition by verapamil of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats.

Authors:  H Uehara; A Nakaizumi; M Baba; H Iishi; M Tatsuta
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.